Information Provided By:
Fly News Breaks for May 7, 2015
VSAR
May 7, 2015 | 07:52 EDT
Canaccord lowered its price target on Versartis to $20 form $45 following the FDA partial clinical hold put on its VRS-317 trial for GHD in children. Canaccord lowered its price target based on a longer timeline to approval and increased development risk. Canaccord maintained its Buy rating, as they believe the stock will react positively if the clinical hold is lifted.
News For VSAR From the Last 2 Days
There are no results for your query VSAR